Acute pancreatitis is a sterile inflammation of the pancreas that triggers a systemic inflammatory response syndrome (SIRS) with great variability in the degree of severity. At Protheragen, we focus on offering complete research services aimed at meeting the demanding need for developing therapeutics for rare diseases like acute pancreatitis. Our goal is to optimize the drug development process, facilitating the access of new therapies to commercialization.

Overview of Acute Pancreatitis

Acute pancreatitis resembles complex inflammation of the pancreas which can further progress to severe acute pancreatitis which has a high mortality rate. Acute pancreatitis has a prevalence of 10 to 50 cases per year in every 100,000 individuals and also affects all age groups. The primary causes of acute pancreatitis include migration of gallstones as well as alcoholism. The disease is characterized principally by abnormal trypsinogen activation inflammation cell infiltration as well as secretive cell destruction. Moderate acute pancreatitis that comes with fluid and/or necrotic collections has considerable morbidity while severe acute pancreatitis also associated with continuous organ failure has substantial mortality rates.

Fig.1 Timeline and therapy of acute pancreatitis. (Trikudanathan, G., et al., 2024)

Pathogenesis of Acute Pancreatitis

The unfavorable pathophysiological processes in acute pancreatitis are illustrated by the inappropriate trypsinogen activation and damage to secretory cells that occur in a cytokine storm. This leads to the activation of inflammatory cells, febrile responses, and MOF. Calcium overload, mitochondrial dysfunction, exosome, impaired autophagy, and endoplasmic reticulum stress represent other contributors to the pathogenesis of the disease.

Fig.2 Atlanta classification of acute pancreatitis. (Zerem, E., et al., 2023)

Therapeutics Development for Acute Pancreatitis

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

The multidisciplinary team of our company provides a customized business model for researchers who specialize in acute pancreatitis and need assistance with diagnosis, therapeutic, and the creation of disease models, which are essential for novel drug development approaches. Our group designs comprehensive preclinical studies that fulfill regulatory standards for drug safety monitoring and pharmacokinetics assessment.

Therapeutic Development Services

Therapeutic Development Services

• Small Molecule Drug
• Cell Therapy Development
• Gene Therapy Development
• Therapeutic Antibody

• Therapeutic Peptide
• Therapeutic Protein
• Microbiome Therapeutic
• More

Animal Model Development Services

• Cerulein-induced animal models
• Cigarette smoke-induced animal models
• Alcohol-induced animal models
• Antibiotic-treated (Abx) animal models

• Sodium taurocholate-induced animal models
• Choline-deficient ethionine-induced animal models
• More

To differentiate ourselves as industry leaders, Protheragen focuses on advancing drug development for individuals suffering from aggravated pancreatitis. Reach out to us to see how our specialized services can increase the efficiency of your drug development projects concerning acute pancreatitis or other uncommon gastrointestinal diseases. Let's partner together in finding better ways to help these individuals live a better life.

References

• Zerem, Enver et al. "Current trends in acute pancreatitis: Diagnostic and therapeutic challenges." World journal of gastroenterology 29.18 (2023): 2747-2763.
• Trikudanathan, Guru et al. "Diagnosis and Management of Acute Pancreatitis." Gastroenterology 167.4 (2024): 673-688.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.